Proteomics International has reported positive results from the clinical validation study of its PromarkerEso diagnostic blood test, designed to detect oesophageal adenocarcinoma.

This test is intended for the early detection and treatment of the illness, a predominant form of oesophagal cancer.

Proteomics’ PromarkerEso blood test is designed to evaluate the levels of four glycoproteins along with a patient's age and BMI to generate a risk score. High-risk patients are advised to undergo an endoscopy.

The test employs a mass spectrometry-based workflow, and results are categorised using a traffic light system to indicate low, moderate, or high risk of oesophageal adenocarcinoma.

Proteomics holds patents for PromarkerEso in Europe, China, and Australia, with other regions pending.

The study involved analysing 165 samples from the Victoria Cancer Biobank, including 66 EAC patients and 99 healthy controls.

The test demonstrated a 94% accuracy and an Area Under the Curve (AUC) of 0.93.

Furthermore, the study reassessed the refined PromarkerEso test on a previously studied cohort from Ochsner, US, confirming its diagnostic accuracy.

These findings complement earlier research that led to the development of the prototype test and validation of the biomarker panel.

Proteomics International managing director Dr Richard Lipscombe said: “We see enormous market potential for a diagnostic test to improve screening and surveillance in at-risk populations. If we can detect oesophageal cancer earlier with PromarkerEso then we can help reduce the enormous cost burden of this disease on healthcare systems and save many lives.”

Looking ahead, Proteomics International is gearing up to launch the PromarkerEso in Australia, targeting the first quarter of calendar year 2025, with plans to expand to other markets subsequently.